Sangamo Therapeutics (STU:GBY) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:GBY Sangamo Therapeutics Inc STU:GBY
33 GF Score
Price €0.11
GF Value €0.30
! 5 Warning Signs
View Full Analysis

What is Sangamo Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

STU:GBY
33GF Score
Sangamo Therapeutics Inc STU:GBY
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sangamo Therapeutics (STU:GBY) Overvalued in 2026?

Based on GuruFocus' analysis, Sangamo Therapeutics stock appears to be undervalued. The current stock price of €0.11 is trading 63.3% below its estimated GF Value™ of €0.30.

Key valuation signals for STU:GBY:

  • FFO:
  • GF Value™: €0.30 vs. price of €0.11 (63.3% below fair value)
  • GF Score™: 33/100 with 5 warning signs

No single metric tells the full story. See the STU:GBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sangamo Therapeutics Business Description

Other Exchanges SGMO:USA0R1D:UK
Address 501 Canal Boulevard, Richmond, CA, USA, 94804
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
33GF Score

Get the complete analysis for STU:GBY

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.30
GF Value